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W
e recently described the targeting 
of O104:H4 Escherichia coli in 
mouse gut by several virulent bacterio-
phages, highlighting several issues relat-
ing to virus-host interactions, which we 
discuss further in this addendum to the 
original publication.
Background
Recent metagenomic studies have con-
firmed that the digestive tract is a com-
plex environment in which bacteria and 
bacteriophages coexist.1 However, little is 
known about the nature of the interactions 
between these two antagonist popula-
tions in this very particular environment. 
Given the constant exposure to bacterio-
phages resulting from food consumption, 
the overall effect of bacteriophages in the 
human gut might be thought to be neg-
ligible as, to our knowledge, no effect of 
bacteriophages has ever been reported. 
However, temperate bacteriophages have 
long been known to play an important 
role in the transfer of genetic informa-
tion between hosts, and it has been shown 
that, as expected, such transfer can occur 
in vivo in mouse gut.2 These findings con-
firmed that prophages, like other mobile 
genetic elements, participate in genomic 
shuffling within the gut microflora.3–5 
However, what do we know about the 
impact of virulent bacteriophages on the 
gut micobiota? Evidence for an active role 
of virulent bacteriophages dates back to 
the first paper to coin the term “bacterio-
phage,” published by Félix d’Herelle, who 
isolated the bacteriophages from patients 
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recovering from dysentery and suggested 
that these organisms played an active 
role in disease recovery. This observation 
formed the cornerstone of a new field, 
phage therapy, which is now returning 
to the fore as a possible solution for treat-
ing bacterial infections due to multidrug-
resistant pathogens.6,7 Several studies have 
investigated the use of virulent bacterio-
phages to treat intestinal infections.8,9 
Possibly the most surprising result of these 
studies was the finding that no common 
pattern could be deciphered for either 
bacteria or bacteriophages. Differences 
in bacteria, bacteriophages and coloniza-
tion or infection models may account for 
this, but this situation contrasts strongly 
with observations in other animal models 
of infection (in the skin, lungs, etc.) for 
which different bacteria and bacterio-
phages have also been evaluated but for 
which highly effective curative action has 
frequently been reported.10 It is therefore 
possible that interactions between bac-
teriophages and bacteria are much more 
complex in the gut than in other organs. 
Our recent article provides a detailed 
illustration of this view, and goes one step 
further, by investigating the limiting fac-
tors for these virus-host interactions in the 
intestine.11
The Bacteriophages
We isolated three bacteriophages, each 
belonging to one of the three families 
of the Caudovirales order, from sew-
age. These bacteriophages (CLB_P1, 
CLB_P2 and CLB_P3) were individually 230  Bacteriophage  Volume 2 issue 4
The Interactions  
of Bacteriophages  
and Bacteria in Animals
Contact between virulent bacteriophages 
and their bacterial hosts triggers an “arms 
race” between the two species. It has been 
reported, in both in vitro and field stud-
ies, that bacteriophage-resistant mutants 
emerge, at various rates, and that variants 
of the bacteriophages subsequently infect 
these new clones.17,18 However, no such 
long-term study has yet been performed in 
the gut environment. Our model, involv-
ing the addition of bacteriophages to the 
drinking water of colonized mice for a 
period of 24 h, leading to the continuous 
replication of bacteriophages within the gut 
over a period of several weeks, provides us 
with an opportunity to address such ques-
tions in vivo, within the digestive tract. 
No bacteriophage resistant mutants were 
observed after three weeks in mice treated 
with the cocktail of three bacteriophages.12 
We also analyzed the three bacteriophages 
individually: CLB_P1 was rapidly cleared   
(< 4 d), CLB_P3 persisted for more than 
twice as long (< 11 d) and CLB_P2 per-
sisted in the gut for at least 30 d without 
selecting for the growth of predominantly 
bacteriophage-resistant mutants (Fig. 1). 
The absence of such mutants in the gut 
was surprising, as we know that bacte-
riophages infect bacteria in this organ, 
exerting a selective pressure on their hosts 
that should lead to the selection of such 
mutants. However, the gut environment 
may not be favorable to the selection of 
bacteriophage-resistant mutants, as such 
mutants may have no selective advantage 
and may be rapidly outcompeted by the 
wild-type strain. This would result in the 
mutants being eliminated from the gut as 
soon as they appeared.
Several hypotheses may be put forward 
to explain why the infection of bacteria 
with bacteriophages did not lead to the 
growth of resistant bacterial clones. First, 
random collisions between bacteriophages 
and bacteria can be artificially increased 
in test tubes, by shaking, whereas such 
collisions are probably much less frequent 
in vivo. Nevertheless, we showed that a 
dose-dependent decrease in the number 
of bacteria in the gut could be obtained 
in vivo, suggesting that the vast majority 
A very closely related clone of the 55989 
strain recently acquired a prophage encod-
ing the Shiga toxin stx2, leading to the 
emergence of highly virulent O104:H4 
stx2+ clones, which caused an outbreak of 
diarrhea and hemolytic uremic syndrome 
affecting 4000 people in Western Europe 
in June 2011.14 Interestingly, CLB_P1 and 
CLB_P2 but not CLB_P3 bacteriophages 
isolated with 55989 strain also infected 
efficiently several of these epidemic 
clones.12
The Animal Model
E. coli strains are not normally consid-
ered to be resident in the mouse intestinal 
microbiota, although there have been spo-
radic reports of their presence.9,15 We used 
an intestinal carriage model in which 
high levels of E. coli are maintained over 
several weeks through the addition of an 
antibiotic to drinking water. This antibi-
otic eliminates part of the natural flora, 
allowing stable colonization by E. coli. In 
the absence of antibiotic pressure, E. coli 
levels decrease over the course of a few 
hours to a few days, depending on the 
strain used.16
Histological analyses of the gut tissues 
of mice after three days of colonization 
with strain 55989 revealed no damage, 
demonstrating that this model mimics, 
in both the small and large intestines, the 
state of asymptomatic carriage found in 
humans for enteroaggregative E. coli.
characterized in vitro on planktonic cul-
tures and on biofilms.12 The T4-like 
bacteriophage CLB_P2 had the best char-
acteristics in vitro, in terms of the lack of 
bacteriophage-resistant clones in plank-
tonic conditions and efficacy on biofilms. 
However, a cocktail of the three bacterio-
phages was more effective against biofilms 
than individual bacteriophages, suggest-
ing a synergistic effect potentially due to 
the combined action of multiple cell wall-
degrading enzymes or a capacity to infect 
multiple physiological stages of the bac-
terium within the biofilm. Surprisingly, 
CLB_P1, a T7-like bacteriophage, was the 
least efficient at reducing biofilms, despite 
the bacteriophage T7 having previously 
been identified as a good candidate for 
therapeutic applications on the basis of in 
vivo experiments.13 It strongly indicated 
that given the high genomic variability of 
bacteriophages generalization of their in 
vivo efficacy cannot be drawn only from 
bacteriophage morphology/classification. 
Finally CLB_P3, a close relative of bacte-
riophage T1, is, to our knowledge, the first 
T1-like bacteriophage ever to be tested in 
an in vivo model.
The Bacteria
A colonization model based on the entero-
aggregative E. coli strain 55989 was the 
starting point of our study. This serotype 
O104:H4 strain was initially isolated from 
an AIDS patient suffering from diarrhea. 
Figure 1. changes in fecal bacteriophage concentration over time in mice colonized with the 
O104:H4 55989 E. coli strain. Four groups of 4 to 5 mice were colonized with E. coli 55989Str on day 
0. three days later, they received normal drinking water or drinking water containing one of the 
bacteriophages studied (closed circles, cLB_P1; squares, cLB_P2; triangles, cLB_P3) or a cocktail 
of the three bacteriophages (dashed line) at a concentration of 1 × 105 pfu/ml each. On day 30, 20 
individual colonies from feces were individually assessed for sensitivity to bacteriophages. the 
concentration of bacteria in the feces over the 30-d period was stable at about 1 × 108 cfu/ml.www.landesbioscience.com Bacteriophage  231
develop a molecular approach (qPCR) to 
quantifying bacteria from samples con-
taining excess bacteriophages (note that a 
DNase treatment step was added prior to 
DNA extraction to eliminate DNA origi-
nating from lysed cells). This excess may 
have been reached because the bacteria 
contained pseudolysogens, making it dif-
ficult to obtain accurate counts by direct 
plating methods. This suggests that some 
published studies may have overestimated 
bacteriophage efficacy, due to the absence 
of bacterial colonies on plates for samples 
containing bacteriophages.
The potential role of pseudolysogeny 
in the maintenance of bacteriophages in 
the gut ecosystem raises many questions 
about interactions of bacteriophages and 
bacteria in animals. If bacterial host cells 
can divide while harboring a pseudolyso-
gen, as suggested by Los et al., it would be 
interesting to determine whether the pseu-
dolysogen persists only in the parental cell 
or whether it is transmitted to the daugh-
ter cells.27 If such transmission occurs, 
does pseudolysogen replication involve 
host factors only, or is a subset of viral pro-
teins involved? If viral genes are expressed 
during the pseudolysogenic stage, do they 
confer a selective advantage on the bacte-
rial host, leading to pseudolysogen main-
tenance? Conversely, if the presence of the 
pseudolysogen is a disadvantage how does 
the host cell eliminate it? This might result 
in abortive infections, which are thought 
to play a role in CRISPR evolution, by 
providing viral spacer sequences.28 During 
pseudolysogeny, allelic exchanges might 
also occur between pseudolysogens and 
bacterial genomes via homologous recom-
bination. Extending this hypothesis to 
the level of the intestinal microbiota 
highlights the potential role of pseudoly-
sogeny in horizontal gene transfer, which 
may contribute to microbiota dynamics. 
Undoubtedly, experimental assessments of 
the role of pseudolysogeny should now be 
further developed.
The Lessons to be Learned
First, our results highlight the need to 
develop molecular approaches for the 
accurate quantification of bacteria. Even 
the simplest determination of bacterial 
counts on Petri dishes was less simple 
prophages in this organ. Our work sug-
gests that bacteria with a low permissiv-
ity to virulent bacteriophage infections 
may also play a role in this phenomenon. 
There may be several reasons for the low 
permissivity to infection observed. For 
example, the localization or expression of 
the bacteriophage receptor at the cell sur-
face may be modified in the gut. This has 
been shown for bacteriophages infecting 
the intestinal pathogen Vibrio cholereae, 
as the pattern of expression of the CTXφ 
and JF9 bacteriophage receptors, TCP and 
CRP, respectively, is modified by environ-
mental conditions along the length of the 
intestine.20–22 Phase variation has also 
been implicated in bacteriophage receptor 
availability at the cell surface.23
In addition to host responses, the viral 
cycle in the gut environment may itself be 
affected. As suggested by several authors, 
pseudolysogeny may play a significant role 
in virus-host interactions in specific envi-
ronmental conditions.24,25 Pseudolysogeny 
is characterized by a “pause” in the clas-
sical lytic cycle. The viral genome is 
maintained in the bacterial cytoplasm in 
a plasmid-like form until favorable condi-
tions for the resumption of the lytic cycle 
occur. Unlike lysogenic phages, pseudoly-
sogenic phages do not integrate into the 
bacterial chromosome.26 Pseudolysogeny 
seems to be entirely dependent on host 
physiology, as no viral gene has yet been 
shown to be involved. This hypothesis is 
supported by our findings that the infec-
tion of E. coli in vivo in the intestine could 
not be inhibited (with DNA damaging 
agents, bacteriophage washout and phage-
receptor interaction competitor agents) 
whereas such inhibition was possible in 
vitro when the strain was grown in LB. 
Indeed, the presence of pseudolysogens 
in the bacterial cytoplasm, where they 
have access to the host DNA repair sys-
tem, may enable them to survive dsDNA 
breaks (caused by damaging agents). 
Moreover, decreasing extracellular bacte-
riophage concentration, either by washout 
or through the use of competitor agents, 
would not change the fate of host cells 
harboring these viral pseudolysogens, as 
they would by lysed when favorable con-
ditions for lytic cycle resumption were 
encountered, such as during the plating 
of samples in Petri dishes. This led us to 
(over 90%) of bacteria could be infected 
by bacteriophages. However, this was not 
enough to trigger the complete elimina-
tion of the bacterial host, suggesting that 
some bacteria may be physically protected 
against bacteriophage infection. Such 
protection might result from the localiza-
tion of bacteria in particular sites inac-
cessible to bacteriophages, such as crypts 
or villi. This population never coming 
into contact with bacteriophages may 
be the source of the wild-type bacteria 
responsible for the renewal of the sensitive 
bacterial population. In contrast to bac-
teriophages that rely on passive diffusion 
to move from one site to another, bacte-
ria actively move within the intestine and 
colonize inaccessible niches giving them 
the possibility to escape bacteriophage 
predation.19 Alternatively, the bacteria 
may be physiologically protected against 
bacteriophage infection. Our ex vivo 
experiments on homogenized colonized 
gut samples revealed that, in this case, the 
bacteria were less permissive to bacterio-
phage infection than bacteria grown in LB 
and subsequently added to homogenized 
non colonized gut samples. This was true 
for bacterial cells isolated from the mouse 
colon, but not from the ileum, reflecting 
the removal of E. coli by bacteriophages 
in the ileum. The metabolism of bacte-
rial cells clearly differs between the small 
and the large intestine, due mainly to dif-
ferences in nutrient availability, and we 
confirmed in vitro that this E. coli strain 
had a lower permissivity to bacteriophage 
infection in stationary phase than in the 
exponential growth phase. The antibiotic 
used to maintain the level of bacterial 
colonization in the gut may counteract 
the effect of the bacteriophages. It is pos-
sible that the selection pressure imposed 
by the antibiotic favors colonization with 
this E. coli strain not only directly, due to 
its resistance, but also indirectly due to a 
lack of metabolic competitors eliminated 
by the antibiotic.
Overall, the low permissivity to bac-
teriophage infection and lack of bacterio-
phage-resistant mutants are consistent with 
the hypothesis put forward by Reyes et al. 
that predator-prey relationships are scarce 
in the intestine.2 These authors suggested 
that the low coevolution dynamics in the 
gut might be due to the predominance of 232  Bacteriophage  Volume 2 issue 4
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interactions between bacteriophages and 
bacteria in the gut. Studies of these aspects 
will improve our ecological understanding 
of this complex environment, potentially 
enhancing the use of bacteriophages to 
treat gut infections, which is dependent 
on such knowledge but also on academic 
and industrial supports as recently high-
lighted by Harald Brüssow.29 However, so 
far laboratory studies focused on the tip 
of an iceberg, the submerged part corre-
sponding to what is likely to be discovered 
in studying bacteriophages in a relevant 
ecological niche. In conclusion, even when 
taking everything we know about interac-
tions between the well-known bacterium 
E. coli and its bacteriophages into account, 
attempts to study these interactions in the 
digestive tract, the real environment of 
E. coli, are likely to modify our current 
knowledge of these interactions, reflecting 
how much we still have to learn about the 
gut microbiome and the complex interac-
tions among its components. 
particular model, the use of in vitro bio-
films before in vivo testing might improve 
predictions of bacteriophage efficacy. 
However, other in vitro models may be 
required to mimic different settings in 
vivo. As it will not be possible to test all 
therapeutic candidates in a pertinent in 
vivo system on a large scale, the search for 
molecular determinants involved in virus-
host interactions in vivo remains essential. 
Such determinants common to all bacte-
riophages are not likely to be identified 
however, we may expect some of them to 
be conserved among genetically closely 
related bacteriophages.
In recent years, microbiology has 
moved from single-celled model organisms 
to more complex environmental systems 
(e.g., lakes, oceans and sites of infection), 
but we need to bear in mind that bacteria 
do not live alone, there are always bacte-
riophages around… and that is as good as 
it gets. Many aspects remain to be eluci-
dated to increase our understanding of the 
than initially anticipated, revealing unex-
pected facets to the gut environment. As 
in all scientific disciplines, reproduc-
ibility is essential for appropriate com-
parisons and the techniques used must 
therefore be reliable. The development of 
molecular approaches, as demonstrated 
by the modest efforts made in our study, 
would certainly increase the reliability of 
results.
Second, we provided evidence that 
not all bacteriophages active in vitro per-
formed as well in vivo. This will undoubt-
edly lead to future studies, but it raises the 
question of how to select the best bacte-
riophages for therapeutic applications? 
Our results clearly indicate that CLB_P2 
was the most suitable of the three bacte-
riophages tested for therapeutic usage, but 
the molecular properties underlying the 
better performance of this bacteriophage 
remain to be determined. We found that 
activities in vitro on biofilms and in vivo 
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